A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Transcutaneous intratracheal injection allows for effective intrapulmonary drug delivery during spontaneous respiration. Single and multiple injections are well tolerated with no effect on survival. The technique is simple to perform and can examine the effect of substances on lung development and the prevention of lung injury in newborn rabbits.

Abstract

Intratracheal (IT) drug delivery allows the direct delivery of pharmaceutical substances to the lung, maximizing potential pulmonary benefit and minimizing systemic drug exposure. The transcutaneous technique is simple and allows for the IT delivery of substances to the lung of prematurely born rabbits shortly after birth. Newborn pups are anesthetized with inhaled Isoflurane before being placed in a supine position with the neck extended. The larynx is identified and stabilized before transcutaneous placement of a 26-gauge (G) catheter into the trachea. Following catheterization of the trachea, a 30 G blunt needle attached to a Hamilton syringe is introduced into the IT catheter and is used for delivering a precise volume into the trachea during spontaneous respiration. After the IT injection is completed, the needle and catheter are withdrawn, and the pup is allowed to recover from anesthesia. Transcutaneous IT injection delivers a large proportion of the injected substance to the lung, with the majority remaining in the lung 3 hours after the intervention. The injections are well tolerated from the day of birth and can be repeated for multiple consecutive days without influencing survival. This technique can be used to investigate the effect of pharmaceutical agents on lung development and in the prevention of neonatal lung injury in preterm rabbits.

Introduction

Chronic neonatal lung disease (CNLD) following premature birth continues to occur in a significant number of infants1. Improved modern neonatal care has significantly increased survival and decreased the majority of significant complications following preterm birth. While neurological, gastrointestinal, and ophthalmological complications have decreased, respiratory complications remain largely unchanged over the past 2 decades with nearly one in two infants born before 28-week gestation developing lung disease.

Prematurity, inflammation, oxidative damage, and ventilator-associated injury all play a role in the pathophysiology of CNLD and poor respiratory outcomes following preterm birth2,3,4. Despite the significant advancements of modern neonatal care, limited effective therapy is available to treat or prevent the development of CNLD5,6.

New approaches and interventions are required to develop therapy to prevent and treat CNLD. Intrapulmonary drug delivery is an attractive intervention to deliver drugs to the lung and could alter the course of respiratory disease in neonates. Intrapulmonary drug therapy has the benefit of direct delivery of active agents to the lung, thereby minimizing accumulation of the drug in off-target organs7,8, potentially limiting systemic side effects. Despite over 2 decades of intrapulmonary surfactant replacement, no additional intrapulmonary drugs have been validated to improve neonatal respiratory outcomes. Recently, budesonide-surfactant combination therapy has been described to improve pulmonary outcomes following preterm birth in mechanically ventilated infants9,10. However, much remains unknown on the functional and structural effects of IT drug therapy, few new therapies have been identified, and the value of intratracheal drug delivery in the neonatal period remains uncertain. Animal models are required to identify potential drugs and aid the development of much needed therapy for CNLD.

Animal studies examining newborn lung disease are most commonly performed in small animal models such as rats and mice11,12,13. The rabbit has the additional advantage of preterm delivery to more closely mimic the structure and function of the immature human lung14. A limitation of the preterm rabbit is the difficulty of accessing the airway to allow the delivery of intrapulmonary interventions. While adult rabbit and rodent models allow trans-oral endotracheal intubation, these techniques are difficult in newborn pups due to their small size and the unique anatomy of the upper airway15,16. Alternative approaches are required to allow access to the trachea for the delivery of drugs in newborn rabbit pups.

In this manuscript, we describe the use of a transcutaneous needle tracheostomy to allow tracheal intubation and drug delivery.

Protocol

For all experiments involving IT injection, permission has been sought from the Animal Ethics Committee of KU Leuven, and all guidelines of animal welfare and care of KU Leuven were adhered to.

1. Preparation

  1. Collect all required materials to complete the IT injection (Table 1).
  2. Ensure that the exhaust of the anesthetic chamber is open and connected to a scavenger to prevent exposing the researcher to Isoflurane.

2. Delivery of pups

NOTE: Rabbit pups (New Zealand white-Flemish giant hybrid) were delivered via hysterotomy on day 28 gestation (term 31 days) during the saccular phase of lung development as previously described by our group17. Pups can be placed in either normoxia to study lung development following preterm birth, or hyperoxia to study acute lung injury.

  1. Sedate dam with an intramuscular injection of 1 mL ketamine (100 mg/mL) and 1 mL xylazine (2%) delivered to the quadriceps with a 2 mL syringe and 26 G needle. Once deeply sedated, place the dam in a supine position on the operating table. Adequate anesthesia is confirmed by deep slow respiration, decreased jaw tone, and the lack of response to an ear pinch.
  2. Shave the central abdomen with an electric shaver and sterilize the surgical field with iodine-based solution.
  3. Euthanize the dam with an intravenous bolus of 1 mL of T61 delivered in the lateral vein of the ear.
  4. Immediately perform a midline abdominal incision through the skin, muscle sheath, and abdominal muscles into the abdominal cavity.
  5. Extend the incision to expose the bicornate uterus.
  6. Immediately make an incision in the uterus using a pair of scissors and deliver each of the pups via the hysterotomy. Rapid delivery of the pups is essential to ensure survival.
  7. On delivery, dry each pup using a paper towel, this both dries and stimulates the pup.
  8. Place the dried pup in the warmed (36 °C), humidified (50% relative humidity) incubator.
  9. Allow 1 h for the recovery and transition to the extra-uterine environment. All the surviving pups are randomized to the predetermined treatment groups.

3. Anesthesia

  1. Flood the induction chamber with Isoflurane (2.5%, 2.5 minimum alveolar concentration (MAC), 2 L/min)
  2. Place pups in the induction chamber until adequate level of anesthesia is achieved (decreased spontaneous movement, diminished foot reflex to painful stimuli, decreased respiratory rate).
    ​NOTE: Eyes of the rabbit pup are not open on day 28 gestational age (as in this experiment) and, therefore, no topical eye ointment is required to prevent dryness of the cornea. Should IT injections be performed later in life, topic ointment should be applied to the open eyes.

4. Positioning for intratracheal injection

  1. Position the pup on the mounting stage, supine with neck extended, and nose inserted into the nosecone to provide continued anesthesia.
  2. Restrain the paws of the pup using non-stretch adhesive tape to tape the paws to the mounting stage.
  3. Identify the tracheal and laryngeal cartilage rings, which are visible as dark subcutaneous midline structure in the upper trachea superior to the thoracic inlet.
  4. Sterilize the skin over the trachea with alcohol solution (80% ethanol solution)
  5. Grasp and stabilize the larynx with Allis forceps with the non-dominant hand of the operator.

5. Performing the intratracheal injection ( Figure 1)

  1. Prepare to cannulate the trachea with the 26 G intravenous cannula (best done with the dominant hand) while stabilizing the trachea with the Allis forceps.
    NOTE: To ensure sterility of the procedure, use a new sterile cannula for each pup.
  2. Penetrate the skin with the cannula at a 45° angle to the skin at the level of the thyroid cartilage.
  3. Slowly advance the cannula and stylet until the trachea is cannulated, a subtle "give" is felt as the needle penetrates the trachea and enters the airway lumen.
  4. Once the cannula with the stylet is in the lumen of the trachea, stop advancing the stylet and advance the plastic cannula over the stylet into the trachea while holding the stylet stationary. Do not advance the plastic cannula >10 mm or selectively intubating either the left or right main bronchus is risked.
  5. Withdraw the stylet from the cannula leaving the plastic cannula sheath in the trachea.
  6. Confirm the IT position of the cannula by injecting a small amount of normal saline (0.9% NaCl, 5 µL) into the cannula using a Hamilton syringe and 30 G blunt needle. Once the saline has been injected into the cannula, remove the Hamilton syringe and needle. Observe the air-fluid level within the plastic cannula; movement of the air-water level in the cannula with spontaneous respiration confirms placement of the cannula within the airway.
  7. Draw up the required amount of substance into the Hamilton syringe using the 30 G blunt tip needle.
  8. Introduce the 30 G blunt tipped needle (attached to the Hamilton syringe) into the plastic cannula (in the trachea), and slowly inject the substance into the trachea over 5-10 s.
  9. Remove the Hamilton syringe needle from the plastic cannula and the plastic cannula from the trachea.

6. Recovery from procedure

  1. Free the pup from the mounting stage and stimulate respiration with tactile stimulation of the pup.
  2. Return the pup to a separate cage from the unanesthetized pups cage in the warmed (36 °C), humidified (50% relative humidity) incubator; place in a 30° head up position until sufficiently recovered from anesthesia and able to maintain sternal recumbency. Do not leave the pups unattended until they recover from the anesthetic.

Results

Representative results of the technique of single and repeated daily transcutaneous IT injections have been published and demonstrate that survival was not influenced by IT injection (single or multiple injections), nor did IT injection with placebo (saline) alter the lung function or lung structure compared to controls18.

Additionally, we have validated the technique in a series of experiments that investigated pulmonary delivery of IT delivered normal saline and surfa...

Discussion

Several critical steps should be followed to successfully perform IT injection. When performed correctly, the transcutaneous IT injection method allows for effective and reliable intrapulmonary drug delivery in the preterm rabbit. Temperature control is important as the newborn pups easily become hypothermic, which can negatively influence survival. Prior to placing the pups in the induction chamber, temperature control should be ensured to maintain normothermic conditions. A heating matt placed under the induction chamb...

Disclosures

The authors have no conflicts of interest to declare.

Acknowledgements

This research was supported by a C2 grant from KU Leuven (C24/18/101) and a research grant from the Research Foundation - Flanders (FWO G0C4419N). A.G. is supported by the Erasmus+ Programme of the European Commission (2013-0040). Y.R. is holder of an FWO-SB fellowship (Research Foundation - Flanders, 1S71619N). None of the funding bodies were involved in the design of the study and in the collection, analysis, and interpretation of data.

Materials

NameCompanyCatalog NumberComments
Anesthesia
Heating matt to prevent cooling during anesthesia1
Isoflurane vaporizer with oxygen supply1
Isoflurane (Iso-Vet; 1000 mg/g)Dechra Veterinary Products NV, Belgium2% at 2 liters/minute
Plexiglas induction chamber with exhaust and scavengerIn house built1
Positioning for injection
Mounting stageIn-house built (made out of styrofoam to allow flexible positioning1
Nose cone connected to anesthetic circuit1
Scavenger system1
Tape to restrain limbsAny1 roll
Intratracheal injection
Allis tissue forceps1
19-mm-long 26-gauge catheterBD Biosciences3913491
Hamilton syringe (10µl with 20 mm blunt 30-gauge needleHamilton Company7638-011
Pharmaceutical substance of choiceas per protocol
Saline (0.9% NaCl)5 µl per animal
Animal housing
Humidity- and temperature-controlled incubatorOkolab Srl. Custom built cage incubator. Alternatively, in-house built cage incubators can be used

References

  1. Stoll, B. J., et al. Trends in care practices, morbidity, and mortality of extremely preterm Neonates, 1993-2012. JAMA - Journal of the American Medical Association. 314 (10), 1039-1051 (2015).
  2. Thekkeveedu, R. K., Guaman, M. C., Shivanna, B. Bronchopulmonary dysplasia A review of pathogenesis and pathophysiology. Respiratory Medicine. 132, 170-177 (2017).
  3. Coalson, J. J. Pathology of bronchopulmonary dysplasia. Seminars in Perinatology. 30 (4), 179-184 (2006).
  4. Leroy, S., et al. A time-based analysis of inflammation in infants at risk of bronchopulmonary dysplasia. Journal of Pediatrics. 192, 60-65 (2018).
  5. Schmidt, B., Roberts, R., Millar, D., Kirpalani, H. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology. 93 (4), 284-287 (2008).
  6. Poets, C. F., Lorenz, L. Prevention of bronchopulmonary dysplasia in extremely low gestational age neonates current evidence. Archives of Disease in Childhood. Fetal and Neonatal Edition. 103 (3), 285-291 (2018).
  7. Garbuzenko, O. B., et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharmaceutical Research. 26 (2), 382-394 (2009).
  8. Stocco, F. G., et al. Comparative pharmacokinetic and electrocardiographic effects of intratracheal and intravenous administration of flecainide in anesthetized pigs. Journal of Cardiovascular Pharmacology. 72 (3), 129-135 (2018).
  9. Yeh, T. F., et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine. 193 (1), 86-95 (2016).
  10. Kothe, T. B., et al. Surfactant and budesonide for respiratory distress syndrome: an observational study. Pediatric Research. 87 (5), 940-945 (2019).
  11. Lignelli, E., Palumbo, F., Myti, D., Morty, R. E. Recent advances in our understanding of the mechanisms of lung alveolarization and bronchopulmonary dysplasia. American Journal of Physiology - Lung Cellular and Molecular Physiology. 317 (6), 832-887 (2019).
  12. Berger, J., Bhandari, V. Animal models of bronchopulmonary dysplasia. The term mouse models. American Journal of Physiology - Lung Cellular and Molecular Physiology. 307 (12), 936-947 (2018).
  13. O'Reilly, M., Thébaud, B. Animal models of bronchopulmonary dysplasia. The term rat models. American Journal of Physiology - Lung Cellular and Molecular Physiology. 307 (12), 948-958 (2014).
  14. Salaets, T., Gie, A., Tack, B., Deprest, J., Toelen, J. Modelling Bronchopulmonary Dysplasia in Animals: Arguments for the Preterm Rabbit Model. Current Pharmaceutical Design. 23 (38), 5887-5901 (2017).
  15. Su, C. S., et al. Efficacious and safe orotracheal intubation for laboratory mice using slim torqueable guidewire-based technique: Comparisons between a modified and a conventional method. BMC Anesthesiology. 16 (1), 1-7 (2016).
  16. Vandivort, T. C., An, D., Parks, W. C. An improved method for rapid intubation of the trachea in mice. Journal of Visualized Experiments. 2016 (108), 1-5 (2016).
  17. Jiménez, J., et al. Progressive vascular functional and structural damage in a bronchopulmonary dysplasia model in preterm rabbits exposed to hyperoxia. International Journal of Molecular Sciences. 17 (10), 1776 (2016).
  18. Salaets, T., et al. Local pulmonary drug delivery in the preterm rabbit: Feasibility and efficacy of daily intratracheal injections. American Journal of Physiology - Lung Cellular and Molecular Physiology. 316 (4), 589-597 (2019).
  19. Bianco, F., et al. From bench to bedside: In vitro and in vivo evaluation of a neonate-focused nebulized surfactant delivery strategy. Respiratory Research. 20 (1), 134 (2019).
  20. Kelly, H. W. Potential adverse effects of the inhaled corticosteroids. The Journal of Allergy and Clinical Immunology. 112 (3), 467-478 (2003).
  21. Gie, A. G., et al. Intratracheal budesonide/surfactant attenuates hyperoxia-induced lung injury in preterm rabbits. American Journal of Physiology - Lung Cellular and Molecular Physiology. 319 (6), 949-956 (2020).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Transcutaneous Drug DeliveryIntratracheal DeliveryNewborn Preterm RabbitPulmonary BenefitSystemic ExposureCatheterizationIsoflurane Anesthesia26 gauge CatheterIT InjectionLung DevelopmentNeonatal Lung InjuryPharmaceutical Agents

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved